{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Resolved prior to end of treatment exposure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Resolved post end of treatment exposure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Not resolved"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The onset of any visual acuity event (change from baseline in logMAR score \\>= 0.3 in either eye) was considered resolved if the change from baseline in logMAR score was less than 0.3 in both eyes. Participants with resolved and not resolved outcome of the worsening eye were presented.","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 178 weeks","title":"Part 2 - Outcome of First Occurrence of Worsening Eye in BCVA Score","type":"SECONDARY","unitOfMeasure":"Participants"}